Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.35 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.35 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 8/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19449576 | 0.77 | BRD4 (0.34) | BRD4CYP19A1LRRK2 | |
| SCHEMBL19449440 | 0.74 | CA1 (0.46) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL19449439 | 0.73 | HSD11B1 (0.43) | CYP19A1LRRK2 | |
| SCHEMBL19449442 | 0.73 | LMNA (0.41) | CYP19A1LRRK2 | |
| SCHEMBL19454813 | 0.71 | RAB9A (0.43) | CYP19A1LRRK2 | |
| SCHEMBL19454748 | 0.70 | CA1 (0.48) | — | |
| SCHEMBL27684365 | 0.68 | CYP1A2 (0.38) | — | |
| SCHEMBL17194913 | 0.68 | TLR8 (0.42) | CYP19A1LRRK2 | |
| SCHEMBL28129241 | 0.66 | ADRA1D (0.46) | BRD4 | |
| SCHEMBL27813515 | 0.66 | KMT2A (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10028938-B2 | Antiviral agents and uses thereof | GRIFFITH UNIVERSITY (AU) | 2018-07-24 | — | — | US | disclosed |
| US-20170290809-A1 | ANTIVIRAL AGENTS AND USES THEREOF | GRIFFITH UNIVERSITY (AU) | 2017-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170290809-A1 | ANTIVIRAL AGENTS AND USES THEREOF | RNASE1, ENTPD5, ACE | BRD4 1940/4885HDAC3 712/4885HDAC4 289/4885 |
| US-10028938-B2 | Antiviral agents and uses thereof | RNASE1, ENTPD5, ACE | BRD4 1940/4885HDAC3 712/4885HDAC4 289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.